A Healthesystems publication

Spring 2013

PDMP: The Game Changer?

Prescription drug abuse could be monitored and prevented if PDMPs are given the funding and attention they deserve.

To continue reading you must be logged in.

Please register for free or login to unlock the rest of this article.

RATE THIS ARTICLE

SOURCES

1 -Julie Worley, “Prescription Drug Monitoring Programs, a Response to Doctor Shopping: Purpose, Effectiveness, and Directions for Future Research,” Issues in Mental Health Nursing, vol. 33, no. 5 (2012), pp. 319-328.
2 -Liza M. Reifler et al., “Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse,” Pain Medicine, no. 13 (2012), pp. 434-442.
3 -Thomas Clark et al, Prescription Drug Monitoring Programs: An Assessment of the Evidence for Best Practices, 6 (2012).
4 -Alliance of States with Prescription Drug Monitoring Programs. Available at: http://www.pmpalliance.org/. Accessed January March 14, 2013.
5 -National Association of State Boards of Pharmacy (NABP), NABP PMP InterConnect, 2012, http://www.nabp.net/ programs/pmp-interconnect/nabp-pmp-interconnect.
6 -National Council for Prescription Drug Programs (NCPDP), NCPDP Recommendations for Improving Prescription Drug Monitoring Programs (PDMP), 2013, Available at: www.ncpdp.org. Accessed March 14, 2013.
7 -Ronald Simeone and Lynn Holland, An Evaluation of Prescription Drug Monitoring Programs, Simeone Associates, Inc., No. 2005PMBXK189, September 1, 2006. Sponsored by the U.S. Department of Justice (DOJ), Office of Justice Programs (OJP), Bureau of Justice Assistance (BJA).
8 -Thomas Clark et al, Prescription Drug Monitoring Programs: An Assessment of the Evidence for Best Practices,6 (2012).
9 -Franklin GM, Stover BD, Turner JA, et al; Disability Risk Identification Study Cohort. Early opioid prescription and subsequent disability among workers with back injuries: the Disability Risk Identification Study Cohort. Spine (Phila Pa 1976) 2008;33(2):199-204.
10 -Webster BS, Verma SK, Gatchel RJ. Relationship between early opioid prescribing for acute occupational low back pain and disability duration, medical costs, subsequent surgery, and late opioid use. Spine (Phila Pa 1976) 2007; 32:2127-2132.
11 -Kidner CL, Mayer TG, Gatchel RJ. Higher opioid doses predict poorer functional outcome in patients with chronic disabling occupational musculoskeletal disorders. J Bone Joint Surg Am. 2009;91(4):919-27.
12 -Leider HL, Dhaliwal J, Davis EJ, et al. Healthcare costs and nonadherence among chronic opioid users. Am J Manag Care. 2011;17(1):32-40.
13 -Alex Swedlow and John Ireland. Estimated Savings from Enhanced Opioid Management Controls Through Third Party Payer Access to CURES. January 2013. California Workers’ Compensation Institute (CWCI).
Table of Contents